Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

24.92
+0.11000.44%
Volume:102.37K
Turnover:2.55M
Market Cap:1.66B
PE:-7.37
High:25.24
Open:24.69
Low:24.46
Close:24.81
52wk High:30.50
52wk Low:14.40
Shares:66.45M
Float Shares:53.21M
Volume Ratio:0.17
T/O Rate:0.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3819
EPS(LYR):-2.4515
ROE:-32.44%
ROA:-21.77%
PB:2.77
PE(LYR):-10.17

Loading ...

Celldex Therapeutics nimmt an mehreren internationalen Investorenkonferenzen teil

Reuters
·
Feb 09

Assessing Celldex Therapeutics (CLDX) Valuation After Recent Share Price Momentum And Ongoing Losses

Simply Wall St.
·
Feb 04

Celldex Expands Into Asthma: Early CDX-622 Trial Signals New Growth Angle for CLDX

TIPRANKS
·
Jan 22

Celldex (CLDX) Gets a Buy from Mizuho Securities

TIPRANKS
·
Jan 09

Barclays Remains a Sell on Celldex (CLDX)

TIPRANKS
·
Jan 09

Bayer And Souffle Therapeutics Partner Up To Advance Cell-Specific Heart-Targeted siRNA Therapy

Reuters
·
Jan 08

Is Celldex (CLDX) Using Barzolvolimab’s Phase 3 Urticaria Bet To Redefine Its Core Strategy?

Simply Wall St.
·
Dec 22, 2025

Celldex Therapeutics Is Maintained at Underweight by Barclays

Dow Jones
·
Dec 18, 2025

Should Celldex’s Global Phase 3 EMBARQ Trial for Barzolvolimab in Inducible Urticaria Require Action From CLDX Investors?

Simply Wall St.
·
Dec 11, 2025

BRIEF-Celldex Initiates Global Registrational Phase 3 Program Of Barzolvolimab In Cold Urticaria And Symptomatic Dermographism

Reuters
·
Dec 09, 2025

Celldex Therapeutics Inc - Data From Open Label Extension Expected in Q1 2026

THOMSON REUTERS
·
Dec 09, 2025

Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

THOMSON REUTERS
·
Dec 09, 2025

Celldex SVP & General Counsel Freddy A. Jimenez Reports Sale of Common Shares

Reuters
·
Dec 09, 2025

How Investors May Respond To Celldex Therapeutics (CLDX) Leadership Change and Widening Third-Quarter Losses

Simply Wall St.
·
Nov 22, 2025

Celldex Therapeutics (CLDX): Assessing Valuation After Recent Revenue Growth and Share Price Swings

Simply Wall St.
·
Nov 19, 2025

Exozymes CEO Unveils Market-Ready Cell-Free Enzyme Technology

Reuters
·
Nov 19, 2025

Celldex Therapeutics Files Initial Beneficial Ownership Statement for SVP & Chief Commercial Officer Teri Lawver

Reuters
·
Nov 13, 2025

Celldex Therapeutics Is Maintained at Underweight by Barclays

Dow Jones
·
Nov 11, 2025

Stifel Nicolaus Sticks to Its Buy Rating for Celldex (CLDX)

TIPRANKS
·
Nov 11, 2025

Mizuho Securities Remains a Buy on Celldex (CLDX)

TIPRANKS
·
Nov 11, 2025